Study on the Use of a Concentrated Growth Factor Preparation Kit for the Treatment of Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-31

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the effectiveness and safety of an autologous platelet-rich concentrated growth factor (CGF) preparation kit for the treatment of knee osteoarthritis in patients diagnosed with this condition. The main question it aims to answer is:

Can the CGF preparation kit effectively improve symptoms and reduce pain in patients with knee osteoarthritis compared to a control intervention? Researchers will compare the CGF treatment group to a control group using platelet-rich plasma (PRP) to see if the CGF intervention results in greater improvements in knee function and pain relief.

Participants will:

Undergo three intra-articular injections of CGF or PRP into the knee joint at weekly intervals.

Complete assessments including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) for pain at specified intervals.

Be monitored for safety and potential adverse events throughout the study period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High Frequency Intensive Autologous PRP Injection and Genicular Nerve Blocks in Treating Knee Osteoarthritis

NCT04088045

Knee Osteoarthritis

UNKNOWN NA

Comparing the Efficacy of Lyophilized Self Growth Factor Versus PRP Injection for Knee OA

NCT06932614

Knee Osteoarthritis PRP Injection

RECRUITING NA

Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis

NCT04006314

Knee Osteoarthritis

UNKNOWN NA

Effect of PRP Joint Cavity Combined with Acupoint Injection on Osteoarthritis of Knee Joint

NCT06688682

Early Knee Osseous Arthrophlogosis

COMPLETED NA

Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis

NCT03329235

Osteoarthritis, Knee

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

As the primary outcome measure of this study relies on subjective evaluation by the participants, a single-blind design is adopted to avoid bias introduced by participants' evaluations. During the informed consent process, investigators should clearly inform participants that they will be randomly assigned to one of the two treatment groups, but they will not be informed of which group they have been allocated to until the end of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CGF Treatment Group

Participants in this arm will receive three intra-articular injections of Concentrated Growth Factor (CGF) prepared using the autologous platelet-rich CGF preparation kit. The injections will be administered at weekly intervals over a period of three weeks.

Group Type EXPERIMENTAL

Concentrated Growth Factor (CGF) Intra-articular Injection

Intervention Type DEVICE

Preparation Method: The CGF is prepared using an autologous platelet-rich preparation kit specifically designed to concentrate growth factors from the patient's own blood. The process involves a specialized centrifugation technique that yields a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and other bioactive molecules.

Rationale: This intervention leverages the body's natural healing response by utilizing autologous growth factors to enhance the repair of cartilage and other joint tissues affected by osteoarthritis. The high concentration of bioactive molecules in CGF is believed to provide a more potent therapeutic effect compared to other platelet-rich therapies.

PRP Treatment Group

Participants in this arm will receive three intra-articular injections of Platelet-Rich Plasma (PRP) prepared using a disposable PRP preparation device. The injections will be administered at weekly intervals over a period of three weeks.

Group Type ACTIVE_COMPARATOR

Platelet-Rich Plasma (PRP) Intra-articular Injection

Intervention Type DEVICE

Preparation Method: The PRP is prepared using a disposable PRP preparation device that separates and concentrates platelets from the patient's blood. This process enriches the plasma with platelets and associated growth factors.

Rationale: PRP has been widely used in clinical practice for its ability to promote tissue healing and reduce inflammation in osteoarthritis. It serves as an active comparator in this study, allowing for a direct comparison of the therapeutic efficacy and safety profile of CGF against a well-established treatment modality.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Concentrated Growth Factor (CGF) Intra-articular Injection

Preparation Method: The CGF is prepared using an autologous platelet-rich preparation kit specifically designed to concentrate growth factors from the patient's own blood. The process involves a specialized centrifugation technique that yields a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and other bioactive molecules.

Rationale: This intervention leverages the body's natural healing response by utilizing autologous growth factors to enhance the repair of cartilage and other joint tissues affected by osteoarthritis. The high concentration of bioactive molecules in CGF is believed to provide a more potent therapeutic effect compared to other platelet-rich therapies.

Intervention Type DEVICE

Platelet-Rich Plasma (PRP) Intra-articular Injection

Preparation Method: The PRP is prepared using a disposable PRP preparation device that separates and concentrates platelets from the patient's blood. This process enriches the plasma with platelets and associated growth factors.

Rationale: PRP has been widely used in clinical practice for its ability to promote tissue healing and reduce inflammation in osteoarthritis. It serves as an active comparator in this study, allowing for a direct comparison of the therapeutic efficacy and safety profile of CGF against a well-established treatment modality.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years, with no gender restrictions;
* Patients diagnosed with knee osteoarthritis according to the "Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2024 Edition)" by the Chinese Osteoarthritis Diagnosis and Treatment Guidelines Expert Group;
* Radiographic evidence of knee osteoarthritis with Kellgren-Lawrence grading of II to IV;
* Visual Analog Scale (VAS) pain score ≥ 4 (moderate or higher pain) and WOMAC score ≥ 24;
* For participants with eligible bilateral knee osteoarthritis, the more severely affected knee will be treated, while the other knee will not be intervened during the study period. If the severity is equal on both sides, the left knee will be selected for intervention;
* The patient or their legal guardian is able to understand the purpose of the study and provide informed consent.

Exclusion Criteria

* Patients with a confirmed diagnosis of other inflammatory diseases of the knee joint, such as rheumatoid arthritis, psoriatic arthritis, or gouty arthritis; Patients with a confirmed diagnosis of bleeding disorders (e.g., allergic purpura, hemophilia, idiopathic thrombocytopenic purpura), hematologic malignancies (e.g., leukemia), or those with unconfirmed bleeding disorders but coagulation dysfunction (coagulation parameters PT, APTT, INR \> 1.5 times the upper limit of normal);
* Patients who have undergone or are planned to undergo knee osteoarthritis surgery within the past 6 months or during the trial period;
* Patients with local infections at the injection site (e.g., septic arthritis, tuberculous arthritis, or local soft tissue infections) or severe systemic infections (e.g., sepsis);
* Patients with untreated malignant diseases such as malignancies, which may interfere with the safety and efficacy assessments of the study and affect the patient's participation in the study;
* Patients with severe hepatic or renal dysfunction \[hepatic function indicators alanine aminotransferase (ALT), aspartate aminotransferase (AST) \> 2 times the upper limit of normal; renal function indicators serum creatinine (Cr), blood urea nitrogen (BUN) \> 2 times the upper limit of normal\];
* Patients with hemoglobin \< 10 g/dL or platelet count \< 125 × 10\^9/L;
* Patients who have used any Chinese or Western medications or therapies for the treatment of knee osteoarthritis within 1 week prior to randomization;
* Patients who have received intra-articular injections or related drug therapies within the past 3 months;
* Women who are planning a pregnancy, breastfeeding, or pregnant during the entire clinical study period;
* Patients who have participated in other interventional drug or medical device clinical trials within 1 month prior to enrollment;
* Other situations where the investigator deems the patient unsuitable for participation in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No